Osaic Holdings’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-56
| Closed | -$558 | – | 7945 |
|
|
2025
Q2 | $558 | Buy |
56
+16
| +40% | +$129 | ﹤0.01% | 7330 |
|
|
2025
Q1 | $238 | Sell |
40
-878
| -96% | -$6.45K | ﹤0.01% | 7143 |
|
|
2024
Q4 | $7.05K | Sell |
918
-318
| -26% | -$2.73K | ﹤0.01% | 5998 |
|
|
2024
Q3 | $12.6K | Sell |
1,236
-283
| -19% | -$4.32K | ﹤0.01% | 5671 |
|
|
2024
Q2 | $22.5K | Buy |
1,519
+505
| +50% | +$7.24K | ﹤0.01% | 5264 |
|
|
2024
Q1 | $13.8K | Buy |
1,014
+365
| +56% | +$3.98K | ﹤0.01% | 5566 |
|
|
2023
Q4 | $7.11K | Buy |
649
+150
| +30% | +$1.49K | ﹤0.01% | 6004 |
|
|
2023
Q3 | $5.46K | Hold |
499
| – | – | ﹤0.01% | 6230 |
|
|
2023
Q2 | $6.61K | Sell |
499
-16
| -3% | -$228 | ﹤0.01% | 6184 |
|
|
2023
Q1 | $7.01K | Hold |
515
| – | – | ﹤0.01% | 6177 |
|
|
2022
Q4 | $10K | Sell |
515
-66
| -11% | -$1.29K | ﹤0.01% | 5931 |
|
|
2022
Q3 | $11K | Sell |
581
-91
| -14% | -$2.1K | ﹤0.01% | 5968 |
|
|
2022
Q2 | $14K | Buy |
672
+668
| +16,700% | +$15.9K | ﹤0.01% | 5851 |
|
|
2022
Q1 | $0 | Buy |
+4
| New | +$145 | ﹤0.01% | 7361 |
|
Other funds holding ITOS
Osaic Holdings's ITOS Position: Q3 2025 in Review
Osaic Holdings sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 56 shares — an estimated $558 sold.
Osaic Holdings first reported a position in ITOS in Q1 2022 and held it in 14 quarters. The position peaked at $22.5K in Q2 2024. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Osaic Holdings reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Osaic Holdings sold 56 iTeos Therapeutics shares in Q3 2025, an estimated $558.
- Osaic Holdings first reported a position in iTeos Therapeutics in Q1 2022 and held it in 14 quarters.
- Osaic Holdings's iTeos Therapeutics position peaked at $22.5K in Q2 2024.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Osaic Holdings's 13F filing for Q3 2025, filed 14 Nov 2025.